2 weeks Ago By ABMN Staff
Federated Hermes Inc. lifted its holdings in Quest Diagnostics Incorporated ( NYSE:DGX – Free Report ) by 232.3% during the fourth quarter, Holdings Channel reports.
The institutional investor owned 1,233 shares of the medical research company’s stock after acquiring an additional 862 shares during the quarter. Federated Hermes Inc.’s holdings in Quest Diagnostics were worth $186,000 as of its most recent SEC filing.
Other institutional investors also recently modified their holdings of the company. Sierra Ocean LLC bought a new stake in Quest Diagnostics during the fourth quarter worth about $33,000. First Financial Corp IN purchased a new position in shares of Quest Diagnostics during the fourth quarter valued at approximately $38,000.
Versant Capital Management Inc boosted its position in shares of Quest Diagnostics by 340.4% in the 4th quarter. Versant Capital Management Inc now owns 251 shares of the medical research company’s stock worth $38,000 after purchasing an additional 194 shares in the last quarter.
FPC Investment Advisory Inc. purchased a new stake in shares of Quest Diagnostics in the 4th quarter worth approximately $45,000. Finally, Global Trust Asset Management LLC bought a new position in Quest Diagnostics during the 4th quarter valued at approximately $49,000.
88.06% of the stock is currently owned by institutional investors. Analyst Upgrades and Downgrades DGX has been the topic of several analyst reports.
Mizuho increased their target price on Quest Diagnostics from $178.00 to $189.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 9th.
Redburn Partners set a $195.00 price target on shares of Quest Diagnostics in a research note on Wednesday, April 2nd. Barclays raised their price objective on shares of Quest Diagnostics from $168.
00 to $175.00 and gave the company an “equal weight” rating in a research note on Friday, January 31st. Leerink Partners upgraded shares of Quest Diagnostics from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $169.
00 to $174.00 in a research note on Monday, January 6th. Finally, Leerink Partnrs raised shares of Quest Diagnostics from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 6th.
Eight research analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $181.33.
Quest Diagnostics Trading Down 0.4 % Shares of NYSE:DGX opened at $163.75 on Friday.
The stock’s 50-day simple moving average is $168.62 and its two-hundred day simple moving average is $160.26.
The stock has a market capitalization of $18.28 billion, a price-to-earnings ratio of 21.29, a PEG ratio of 2.
16 and a beta of 0.78. Quest Diagnostics Incorporated has a 52-week low of $126.
08 and a 52-week high of $178.87. The company has a debt-to-equity ratio of 0.
82, a quick ratio of 1.02 and a current ratio of 1.10.
Quest Diagnostics ( NYSE:DGX – Get Free Report ) last posted its quarterly earnings data on Thursday, January 30th. The medical research company reported $2.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.
19 by $0.04. Quest Diagnostics had a net margin of 8.
80% and a return on equity of 15.07%. Analysts expect that Quest Diagnostics Incorporated will post 9.
7 EPS for the current year. Quest Diagnostics Increases Dividend The business also recently announced a quarterly dividend, which will be paid on Monday, April 21st. Investors of record on Monday, April 7th will be issued a $0.
80 dividend. This is a boost from Quest Diagnostics’s previous quarterly dividend of $0.75.
This represents a $3.20 dividend on an annualized basis and a yield of 1.95%.
The ex-dividend date of this dividend is Monday, April 7th. Quest Diagnostics’s dividend payout ratio (DPR) is currently 41.61%.
Insider Activity at Quest Diagnostics In other news, CEO J. E. Davis sold 39,191 shares of the firm’s stock in a transaction on Wednesday, April 2nd.
The shares were sold at an average price of $168.46, for a total transaction of $6,602,115.86.
Following the sale, the chief executive officer now directly owns 127,623 shares in the company, valued at $21,499,370.58. This trade represents a 23.
49 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink . Also, EVP Catherine T.
Doherty sold 5,370 shares of the company’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $174.13, for a total transaction of $935,078.
10. Following the completion of the transaction, the executive vice president now directly owns 68,068 shares of the company’s stock, valued at $11,852,680.84.
This represents a 7.31 % decrease in their position. The disclosure for this sale can be found here .
Over the last three months, insiders have sold 55,903 shares of company stock worth $9,460,221. Corporate insiders own 8.16% of the company’s stock.
Quest Diagnostics Profile ( Free Report ) Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. Recommended Stories Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated ( NYSE:DGX – Free Report ). Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter .
.
